Arnaud Béduneau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1233790/publications.pdf Version: 2024-02-01



Δρηλιής ΒΑΩσιινελίι

#	Article	IF	CITATIONS
1	Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting. Pharmaceutics, 2022, 14, 352.	2.0	5
2	Size effect and mucus role on the intestinal toxicity of the E551 food additive and engineered silica nanoparticles. Nanotoxicology, 2022, 16, 165-182.	1.6	4
3	Toxicity assessment of nanoparticles in contact with the skin. Journal of Nanoparticle Research, 2022, 24, .	0.8	10
4	Amelioration of murine experimental colitis using biocompatible cyclosporine A lipid carriers. Drug Delivery and Translational Research, 2021, 11, 1301-1308.	3.0	2
5	Investigation of the spontaneous nanoemulsification process with medium- and long-chain triglycerides. Colloids and Surfaces B: Biointerfaces, 2021, 197, 111432.	2.5	7
6	Hyaluronic Acid Increases Anti-Inflammatory Efficacy of Rectal 5-Amino Salicylic Acid Administration in a Murine Colitis Model. Biomolecules and Therapeutics, 2021, 29, 536-544.	1.1	3
7	Characterization and biodistribution of Au nanoparticles loaded in PLGA nanocarriers using an original encapsulation process. Colloids and Surfaces B: Biointerfaces, 2021, 205, 111875.	2.5	10
8	Anti-inflammatory effects of acacia and guar gum in 5-amino salicylic acid formulations in experimental colitis. International Journal of Pharmaceutics: X, 2021, 3, 100080.	1.2	8
9	Influence of nanoparticles on liver tissue and hepatic functions: A review. Toxicology, 2020, 430, 152344.	2.0	32
10	Anti-Inflammatory Activity of Chitosan and 5-Amino Salicylic Acid Combinations in Experimental Colitis. Pharmaceutics, 2020, 12, 1038.	2.0	20
11	Crosslinked Fibroin Nanoparticles: Investigations on Biostability, Cytotoxicity, and Cellular Internalization. Pharmaceuticals, 2020, 13, 86.	1.7	15
12	Small silica nanoparticles transiently modulate the intestinal permeability by actin cytoskeleton disruption in both Caco-2 and Caco-2/HT29-MTX models. Archives of Toxicology, 2020, 94, 1191-1202.	1.9	32
13	Nanosphere-shaped ammonio methacrylate copolymers: converting a pharmaceutical inactive ingredient to efficient therapeutics for experimental colitis. Nanoscale, 2020, 12, 9590-9602.	2.8	4
14	Interspecies differences in the cytochrome P450 activity of hepatocytes exposed to PLGA and silica nanoparticles: an in vitro and in vivo investigation. Nanoscale, 2018, 10, 5171-5181.	2.8	14
15	A nanoparticle-based approach to improve the outcome of cancer active immunotherapy with lipopolysaccharides. Drug Delivery, 2018, 25, 1414-1425.	2.5	23
16	Nanoparticle-based delivery enhances anti-inflammatory effect of low molecular weight heparin in experimental ulcerative colitis. Drug Delivery, 2017, 24, 811-817.	2.5	24
17	In-vitro investigation regarding the effects of Gelucire ® 44/14 and Labrasol® ALF on the secretory intestinal transport of P-gp substrates. International Journal of Pharmaceutics, 2016, 515, 293-299.	2.6	14
18	Triterpenoid Saponins from the Caryophyllaceae Family Modulate the Efflux Activity of the P-Clycoprotein in an In Vitro Model of Intestinal Barrier. Planta Medica, 2016, 82, 1553-1557.	0.7	3

Arnaud Béduneau

#	Article	IF	CITATIONS
19	Size dependent skin penetration of nanoparticles in murine and porcine dermatitis models. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 100, 101-108.	2.0	46
20	Biorelevant media resistant co-culture model mimicking permeability of human intestine. International Journal of Pharmaceutics, 2015, 481, 27-36.	2.6	30
21	Liposomes Coloaded with Elacridar and Tariquidar To Modulate the P-Glycoprotein at the Blood–Brain Barrier. Molecular Pharmaceutics, 2015, 12, 3829-3838.	2.3	10
22	Stability of fluorescent labels in PLCA polymeric nanoparticles: Quantum dots versus organic dyes. International Journal of Pharmaceutics, 2015, 494, 471-478.	2.6	36
23	Ion milling coupled field emission scanning electron microscopy reveals current misunderstanding of morphology of polymeric nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 89, 56-61.	2.0	14
24	Coadministration of P-Glycoprotein Modulators on Loperamide Pharmacokinetics and Brain Distribution. Drug Metabolism and Disposition, 2014, 42, 700-706.	1.7	42
25	A tunable Caco-2/HT29-MTX co-culture model mimicking variable permeabilities of the human intestine obtained by an original seeding procedure. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 290-298.	2.0	154
26	Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis. Journal of Controlled Release, 2014, 188, 9-17.	4.8	76
27	Surfactant-dependence of nanoparticle treatment in murine experimental colitis. Journal of Controlled Release, 2013, 172, 62-68.	4.8	27
28	Oral insulin delivery in rats by nanoparticles prepared with non-toxic solvents. International Journal of Pharmaceutics, 2013, 443, 169-174.	2.6	25
29	A "drug cocktail―delivered by microspheres for the local treatment of rat glioblastoma. Journal of Microencapsulation, 2013, 30, 667-673.	1.2	8
30	Nanoparticle Targeting to Inflamed Tissues of the Gastrointestinal Tract. Current Drug Delivery, 2013, 10, 9-17.	0.8	12
31	Surface-Charge-Dependent Nanoparticles Accumulation in Inflamed Skin. Journal of Pharmaceutical Sciences, 2012, 101, 4231-4239.	1.6	49
32	Bioadhesive pellets increase local 5-aminosalicylic acid concentration in experimental colitis. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 379-385.	2.0	35
33	Nanoparticles enhance therapeutic outcome in inflamed skin therapy. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 151-157.	2.0	76
34	Nanoparticle-based clodronate delivery mitigates murine experimental colitis. Journal of Controlled Release, 2012, 160, 659-665.	4.8	56
35	Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes. Journal of Controlled Release, 2012, 161, 50-61.	4.8	75
36	Surfactant dependent toxicity of lipid nanocapsules in HaCaT cells. International Journal of Pharmaceutics, 2011, 411, 136-141.	2.6	80

Arnaud Béduneau

#	Article	IF	CITATIONS
37	Colonic delivery of carboxyfluorescein by pH-sensitive microspheres in experimental colitis. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 290-295.	2.0	18
38	pH-sensitive microparticles prepared by an oil/water emulsification method using n-butanol. International Journal of Pharmaceutics, 2009, 375, 61-66.	2.6	13
39	Facilitated Monocyte-Macrophage Uptake and Tissue Distribution of Superparmagnetic Iron-Oxide Nanoparticles. PLoS ONE, 2009, 4, e4343.	1.1	116
40	Brain targeting using novel lipid nanovectors. Journal of Controlled Release, 2008, 126, 44-49.	4.8	95
41	Salting-Out Effect Induced by Temperature Cycling on a Water/Nonionic Surfactant/Oil System. Journal of Physical Chemistry B, 2007, 111, 3651-3657.	1.2	53
42	Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab' fragments. Biomaterials, 2007, 28, 4978-4990.	5.7	143
43	Active targeting of brain tumors using nanocarriers. Biomaterials, 2007, 28, 4947-4967.	5.7	400
44	Pegylated Nanocapsules Produced by an Organic Solvent-Free Method: Evaluation of their Stealth Properties. Pharmaceutical Research, 2006, 23, 2190-2199.	1.7	67